Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A

Neurobiology of Disease

Volumn 48, Issue 3, 2012, Pages 367-378

  Shimizu, Toshihiko ^a   Shibata, Mamoru ^a   Toriumi, Haruki ^a   Iwashita, Tatsuo ^a   Funakubo, Megumi ^a   Sato, Hitoshi ^a   Kuroi, Toshiya ^a   Ebine, Taeko ^a   Koizumi, Kenzo ^a   Suzuki, Norihiro ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Botulinum neurotoxin type A; Craniofacial pain; Exocytosis; Migraine; Trigeminal ganglion; TRPV1

Indexed keywords

BOTULINUM TOXIN A; PROTEOME; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; VANILLOID RECEPTOR 1;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CELL STRAIN; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG MECHANISM; DURA MATER; GENETIC TRANSFECTION; HISTOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MOUSE; NERVE CELL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIGEMINUS GANGLION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BOTULINUM TOXINS, TYPE A; IMMUNOHISTOCHEMISTRY; MALE; NEUROMUSCULAR AGENTS; NEURONS; PAIN; PC12 CELLS; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TRIGEMINAL GANGLION; TRPV CATION CHANNELS;

EID: 84864921723     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.07.010     Document Type: Article

References (40)

1. Akbar A., Yiangou Y., Facer P., Brydon W.G., Walters J.R., Anand P., Ghosh S. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010, 59:767-774.
2. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 2008, 28:3689-3696.
3. Apostolidis A., Popat R., Yiangou Y., Cockayne D., Ford A.P., Davis J.B., Dasgupta P., Fowler C.J., Anand P. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J. Urol. 2005, 174:977-982. (discussion 982-3).
4. Aurora S.K., Dodick D.W., Turkel C.C., DeGryse R.E., Silberstein S.D., Lipton R.B., Diener H.C., Brin M.F. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30:793-803.
5. Bhave G., Hu H.J., Glauner K.S., Zhu W., Wang H., Brasier D.J., Oxford G.S., Gereau R.W.T. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12480-12485.
6. Bonnington J.K., McNaughton P.A. Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor. J. Physiol. 2003, 551:433-446.
7. Camprubí-Robles M., Planells-Cases R., Ferrer-Montiel A. Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors. FASEB J. 2009, 23:3722-3733.
8. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288:306-313.
9. Diener H.C., Dodick D.W., Aurora S.K., Turkel C.C., DeGryse R.E., Lipton R.B., Silberstein S.D., Brin M.F. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010, 30:804-814.
10. Dolly J.O., Lawrence G.W., Meng J., Wang J., Ovsepian S.V. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr. Opin. Pharmacol. 2009, 9:326-335.
11. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
12. Gavva N.R., Treanor J.J., Garami A., Fang L., Surapaneni S., Akrami A., Alvarez F., Bak A., Darling M., Gore A., Jang G.R., Kesslak J.P., Ni L., Norman M.H., Palluconi G., Rose M.J., Salfi M., Tan E., Romanovsky A.A., Banfield C., Davar G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008, 136:202-210.
13. Gazerani P., Pedersen N.S., Staahl C., Drewes A.M., Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009, 141:60-69.
14. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
15. Gunthorpe M.J., Chizh B.A. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov. Today 2009, 14:56-67.
16. Honda K., Kitagawa J., Sessle B.J., Kondo M., Tsuboi Y., Yonehara Y., Iwata K. Mechanisms involved in an increment of multimodal excitability of medullary and upper cervical dorsal horn neurons following cutaneous capsaicin treatment. Mol. Pain 2008, 4:59.
17. Kato A., Rouach N., Nicoll R.A., Bredt D.S. Activity-dependent NMDA receptor degradation mediated by retrotranslocation and ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5600-5605.
18. Kitamura Y., Matsuka Y., Spigelman I., Ishihara Y., Yamamoto Y., Sonoyama W., Kamioka H., Yamashiro T., Kuboki T., Oguma K. Botulinum toxin type a (150kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 2009, 159:1422-1429.
19. Lee L.Y., Gu Q. Role of TRPV1 in inflammation-induced airway hypersensitivity. Curr. Opin. Pharmacol. 2009, 9:243-249.
20. Lim E.C., Seet R.C. Use of botulinum toxin in the neurology clinic. Nat. Rev. Neurol. 2010, 6:624-636.
21. Matak I., Bach-Rojecky L., Filipovic B., Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011, 186:201-207.
22. Meents J.E., Neeb L., Reuter U. TRPV1 in migraine pathophysiology. Trends Mol. Med. 2010, 16:153-159.
23. Meng J., Wang J., Lawrence G., Dolly J.O. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J. Cell Sci. 2007, 120:2864-2874.
24. Mizushima N., Yoshimori T., Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
25. Morenilla-Palao C., Planells-Cases R., García-Sanz N., Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J. Biol. Chem. 2004, 279:25665-25672.
26. Moskowitz M.A. The neurobiology of vascular head pain. Ann. Neurol. 1984, 16:157-168.
27. Naumann M., So Y., Argoff C.E., Childers M.K., Dykstra D.D., Gronseth G.S., Jabbari B., Kaufmann H.C., Schurch B., Silberstein S.D., Simpson D.M. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1707-1714.
28. Romanovsky A.A., Almeida M.C., Garami A., Steiner A.A., Norman M.H., Morrison S.F., Nakamura K., Burmeister J.J., Nucci T.B. The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. Pharmacol. Rev. 2009, 61:228-261.
29. Südhof T.C., Rothman J.E. Membrane fusion: grappling with SNARE and SM proteins. Science 2009, 323:474-477.
30. Shah B.H., Catt K.J. Calcium-independent activation of extracellularly regulated kinases 1 and 2 by angiotensin II in hepatic C9 cells: roles of protein kinase Cdelta, Src/proline-rich tyrosine kinase 2, and epidermal growth receptor trans-activation. Mol. Pharmacol. 2002, 61:343-351.
31. Shimada S.G., LaMotte R.H. Behavioral differentiation between itch and pain in mouse. Pain 2008, 139:681-687.
32. Shimizu T., Toriumi H., Sato H., Shibata M., Nagata E., Gotoh K., Suzuki N. Distribution and origin of TRPV1 receptor-containing nerve fibers in the dura mater of rat. Brain Res. 2007, 1173:84-91.
33. Shinoda M., Kawashima K., Ozaki N., Asai H., Nagamine K., Sugiura Y. P2X3 receptor mediates heat hyperalgesia in a rat model of trigeminal neuropathic pain. J. Pain 2007, 8:588-597.
34. Shinoda M., Ozaki N., Sugiura Y. Involvement of ATP and its receptors on nociception in rat model of masseter muscle pain. Pain 2008, 134:148-157.
35. Staikopoulos V., Sessle B.J., Furness J.B., Jennings E.A. Localization of P2X2 and P2X3 receptors in rat trigeminal ganglion neurons. Neuroscience 2007, 144:208-216.
36. Stein A.T., Ufret-Vincenty C.A., Hua L., Santana L.F., Gordon S.E. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J. Gen. Physiol. 2006, 128:509-522.
37. Szallasi A., Cruz F., Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs?. Trends Mol. Med. 2006, 12:545-554.
38. Van Buren J.J., Bhat S., Rotello R., Pauza M.E., Premkumar L.S. Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol. Pain 2005, 1:17.
39. Zhang X., Huang J., McNaughton P.A. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 2005, 24:4211-4223.
40. Zhu W., Oxford G.S. Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1. Mol. Cell. Neurosci. 2007, 34:689-700.